Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.
1. A composition comprising microparticles having a diameter between 0.5 and 1000 μm, comprising a diketopiperazine and polysorbate 80, wherein the microparticles are coated with an active agent.
2. The composition of claim 1 , wherein the diketopiperazine is crystalline.
3. The composition of claim 2 , wherein the diketopiperazine is selected from the group consisting of: 3,6-di(4-aminobutyl)-2,5-diketopiperazine; 3,6-di(succinyl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(maleyl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(citraconyl-4-aminobutyl)-2-5-diketopiperazine; 3,6-di(glutaryl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(malonyl-4-aminobutyl)-2,5-diketopiperazine; 3,6-di(oxalyl-4-aminobutyl)-2,5-diketopiperazine; and 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine.
4. The composition of claim 1 , wherein the diketopiperazine is 3,6-di(4-aminobutyl)-2,5-diketopiperazine.
5. The composition of claim 1 , wherein the active agent is adsorbed to crystalline surfaces of the diketopiperazine.
6. The composition of claim 5 , wherein the active agent is adsorbed to the crystalline surfaces of the diketopiperazine by an electrostatic, polar, ionic, hydrophobic, hydrogen bonding, or van der Waals interaction.
7. The composition of claim 5 , wherein the active agent forms a coating comprising a monolayer on the crystalline surfaces of the diketopiperazine.
8. The composition of claim 1 , wherein the coating is about 11.4% of the total weight of the microparticle.
9. The composition of claim 1 , comprising approximately 0.8% w/w polysorbate 80.
10. The composition of claim 1 , wherein the active agent is selected from the group consisting of insulin or an analog thereof, growth hormone, parathyroid hormone (PTH), ghrelin, granulocyte macrophage colony stimulating factor (GM-CSF), glucagon-like peptide 1 (GLP-1), antibodies and fragments thereof, and cyclosporins.
11. The composition of claim 1 , wherein the active agent comprises insulin or analog thereof.
12. A pharmaceutical composition for pulmonary delivery comprising microparticles of a diketopiperazine, a polysorbate 80 and an active agent.
13. The pharmaceutical composition of claim 12 , wherein the diketopiperazine forms microparticles having crystalline surfaces.
14. The pharmaceutical composition of claim 13 , wherein the diketopiperazine is 3,6-di(4-aminobutyl)-2,5-diketopiperazine.
15. The pharmaceutical composition of claim 13 , wherein the active agent forms a coating comprising a monolayer on the crystalline surfaces.
16. The pharmaceutical composition of claim 15 , wherein the coating is about 11.4% of the total weight of the microparticles.
17. The pharmaceutical composition of claim 12 , comprising between 0.7% and 3.5% w/w polysorbate 80.
18. The pharmaceutical composition of claim 12 , wherein the active agent is selected from the group consisting of vasoactive agents, neuroactive agents, hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antiviral agents, antigens, antibodies, insulin and analogs thereof, growth hormone, parathyroid hormone (PTH), ghrelin, granulocyte macrophage colony stimulating factor (GM-CSF), glucagon-like peptide 1 (GLP-1), cyclosporins, clopiogrel and PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone), antibodies and fragments thereof, humanized or chimeric antibodies; F(ab), F(ab) 2 , or single-chain antibody alone or fused to other polypeptides; therapeutic or diagnostic monoclonal antibodies to cancer antigens, cytokines, infectious agents, inflammatory mediators, hormones, and cell surface antigens, anti-SSX-2 41-49 (synovial sarcoma, X breakpoint 2), anti-NY-ESO-1 (esophageal tumor associated antigen), anti-PRAME (preferentially expressed antigen of melanoma), anti-PSMA (prostate-specific membrane antigen), anti-Melan-A (melanoma tumor associated antigen), anti-tyrosinase (melanoma tumor associated antigen), and anti-MOPC-21 (myeloma plasma-cell protein).
19. The pharmaceutical composition of claim 12 , wherein the active agent is a vasoactive agent or a neuroactive agent.